Get a quick, expert overview of the latest clinical information and guidelines for cancer checkpoint inhibitors and their implications for specific types of cancers. This practical title by Drs. Fumito Ito and Marc Ernstoff synthesizes the most up-to-date research and clinical guidance available on immune checkpoint inhibitors and presents this information in a compact, easy-to-digest resource. It's an ideal concise reference for trainee and practicing medical oncologists, as well as those in research. - Discusses the current understanding of how to best harness the immune system against different types of cancer at various stages. - Helps you translate current research and literature into practical information for daily practice. - Presents information logically organized by disease site. - Covers tumor immunology and biology; toxicities associated with immune checkpoint inhibitors; and future outlooks. - Consolidates today's available information on this timely topic into one convenient resource.

This book is a practical guide on how best to incorporate advanced radiation therapy techniques into the multimodality treatment of a wide range of gastrointestinal tumors, including esophageal cancer, gastric cancer, hepatobiliary malignancies (primary and metastatic liver tumors, intrahepatic, perihilar, and extrahepatic cholangiocarcinomas, and gallbladder cancer), pancreatic cancer, colorectal cancer, and carcinoma of the anal canal. Practical considerations when treating patients with external beam radiation therapy, intensity-modulated radiation therapy, particle therapy, and stereotactic body radiation therapy are clearly explained. Detailed attention is devoted to the safety and efficacy of radiotherapy in combination with current and emerging systemic therapies (chemotherapy, immunotherapy, and biologic agents), surgery, and ablative therapy, and the advantages and disadvantages of alternative treatment approaches for different tumor types are carefully evaluated. The book will benefit radiation oncologists, medical and surgical oncologists, medical physicists, medical dosimetrists, and other oncology professionals.

Handbook of Gastrointestinal Cancers is a practical guide to the management of colorectal, pancreatic, hepatocellular, gastric, and esophageal cancers as well as other cancers of the upper and lower gastrointestinal tract. Edited by a multidisciplinary group of oncologists from leading institutions, this book is an essential day-to-day reference for evidence-based treatment and patient care. The handbook focuses on treatment strategies and approaches to cancerous gastrointestinal tumors that are transforming the recent oncological landscape, including expert-given guidance on methods such as neoadjuvant and adjuvant chemotherapy, surgical transplant, radiation therapy, molecular diagnostic testing leading to molecularly targeted therapy, and immunotherapy. With so many advances in the current field, it is increasingly difficult for early-career practitioners to grasp the entirety of practices and for seasoned oncologists to keep up with newly approved therapies, side effects to treatments, and special clinical management considerations, but this handbook addresses it all. Organized by major gastrointestinal disease sites and featuring “How I Treat” case vignettes from world experts for common and uncommon management considerations, the handbook brings an experience-based perspective to these tough-to-treat areas. The treatment strategies and applications set forth in the chapters are pertinent to situations and decision-making encountered in practice. Handbook of Gastrointestinal Cancers is a valuable resource for medical oncologists, radiation oncologists, and surgeons treating and managing gastrointestinal cancers as well as trainees in medical, radiation, and surgical oncology programs needing an accessible point of care resource. KEY FEATURES: Provides treatment plans and recommendations for each stage of a range of gastrointestinal cancers, including colorectal, pancreatic, and hepatocellular cancers plus more Includes “How I Treat” patient vignettes told from the physician’s point of view within each clinical chapter Outlines special considerations for the elderly and for survivors of gastrointestinal cancers Highlights important clinical guidance on nutritional and palliative concerns commonly seen in patients with gastrointestinal cancers

This book reviews current immunotherapeutic strategies for gastrointestinal (GI) malignancies, including immune composition, immune checkpoint inhibitors, cell therapy, and peptide vaccines used to protect against esophageal, gastric, hepato-biliary, pancreatic and colorectal cancers. It also discusses the current challenges of using immunotherapy for the treatment of gastrointestinal malignancies. The book reviews highly sensitive and specific immunomarkers for the detection of GI malignancies, and examines therapeutic vaccines and the major cytokines involved in GI immunotherapy, as well as their basic biology and clinical applications. In closing, the book explores various aspects of computational biology for the detection and treatment of GI malignancies.

This book is about the manipulation of the immune system as a therapeutic approach to gastrointestinal cancer and its clinical applications, exploring therapeutic approaches which might be taken under the broad banner of immunotherapy. Starting by introducing concepts of modern immunology, the clinical applications of immunotherapy are then discussed. The reader will learn about the three broad classes of immune therapeutic agents: cell-based treatment; antibody therapy; cytokine application and the key effector cells and mechanisms which might cause tumour rejection. The reverse side of this equation, the genetic and molecular mechanisms which the tumour can use to escape immune control and regulation, is also discussed. Through reviewing the most up-to-date evidence, this volume provides an overview of the important scientific lessons learned from past failure of immunotherapeutics in the clinic and highlights more positive recent data, coupled to practical guidelines for clinical usage. Written by a team of worldwide experts, this is an indispensable guide for medical oncologists, surgical oncologists, radiation therapists, pharmacists, oncology nurse specialists.

Drug-Induced Liver Injury, Volume 85, the newest volume in the Advances in Pharmacology series, presents a variety of chapters from the best authors in the field. Chapters in this new release include Cell death mechanisms in DILI, Mitochondria in DILI, Primary hepatocytes and their cultures for the testing of drug-induced liver injury, MetaHeps an alternate approach to identify IDILI, Autophagy and DILI, Biomarkers and DILI, Regeneration and DILI, Drug-induced liver injury in obesity and nonalcoholic fatty liver disease, Mechanisms of Idiosyncratic Drug-Induced Liver Injury, the Evaluation and Treatment of Acetaminophen Toxicity, and much more. - Includes the authority and expertise of leading contributors in pharmacology - Presents the latest release in the Advances in Pharmacology series

Gastric cancer has been one of the great malignant scourges affecting man kind for as long as medical records have been kept. Until operative resection pioneered by Bilroth and others became available, no effective treatment was feasible and death from cancer was virtually inevitable. Even with resection by total gastrectomy, the chances of tumor eradication remained small. Over recent years, however, the situation has been changing. Some changes have resulted from better understanding of the disease, early detec tion, and better management techniques with applied clinical research, but the reasons for other changes are poorly understood. For example, the incidence of gastric cancer is decreasing, especially in westernized societies, where it has fallen from one of the most common cancers to no longer being in the top five causes of cancer death. Still it remains the number one killer of adult males in Japan and Korea. Whether the reduced incidence in western societies is a result of dietary changes or methods of food preservation, or some other reason, is as yet uncertain. Improvements in outcome have been reported from mass screening and early detection; more refined techniques of establishing early diagnosis, tumor type, and tumor extent; more radical surgical resection; and resection at earlier stages of disease.